Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20186907 | 0.98 | CYP19A1 (0.53) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL5999494 | 0.94 | CYP19A1 (0.50) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| Hydrochloric Acid SCHEMBL27518112 | 0.92 | CYP19A1 (0.49) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL5998626 | 0.89 | CYP19A1 (0.54) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL6000245 | 0.87 | CYP19A1 (0.49) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL3235238 | 0.86 | CYP19A1 (0.55) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL29676826 | 0.86 | CYP19A1 (0.55) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL5999890 | 0.86 | CYP19A1 (0.56) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL5999982 | 0.84 | CYP19A1 (0.42) | CYP19A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL6000000 | 0.84 | CYP19A1 (0.62) | CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| EP-1781635-A4 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1781635-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015159-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | CYP19A1 1608/4885CYP1A2 1249/4885CYP3A4 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.